Norges Bank
ARQT icon

Norges Bank’s Arcutis Biotherapeutics ARQT Stock Holding History

Norges Bank’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.3M Buy
+392,300
New +$9.14M ﹤0.01% 1285
2026
Q1 		– Sell
-174,820
Closed -$5.08M – 108
2025
Q4 		$5.08M Buy
+174,820
New +$4.48M ﹤0.01% 1385
2025
Q3 		– Sell
-174,820
Closed -$2.45M – 124
2025
Q2 		$2.45M Sell
174,820
-504,500
-74% -$7.07M ﹤0.01% 1401
2025
Q1 		$10.6M Buy
679,320
+146,527
+28% +$2.06M ﹤0.01% 1271
2024
Q4 		$7.42M Buy
532,793
+357,973
+205% +$3.92M ﹤0.01% 1409
2024
Q3 		$1.63M Hold
174,820
– – ﹤0.01% 1681
2024
Q2 		$1.63M Hold
174,820
– – ﹤0.01% 1757
2024
Q1 		$1.73M Buy
174,820
+93,808
+116% +$700K ﹤0.01% 1748
2023
Q4 		$262K Hold
81,012
– – ﹤0.01% 1920
2023
Q3 		$430K Hold
81,012
– – ﹤0.01% 1927
2023
Q2 		$772K Hold
81,012
– – ﹤0.01% 1946
2023
Q1 		$891K Hold
81,012
– – ﹤0.01% 2012
2022
Q4 		$1.2M Hold
81,012
– – ﹤0.01% 2034
2022
Q3 		$1.55M Buy
81,012
+19,896
+33% +$451K ﹤0.01% 1946
2022
Q2 		$1.3M Hold
61,116
– – ﹤0.01% 1940
2022
Q1 		$1.18M Sell
61,116
-204,277
-77% -$3.46M ﹤0.01% 2032
2021
Q4 		$5.5M Buy
265,393
+204,277
+334% +$4.07M ﹤0.01% 1897
2021
Q3 		$1.46M Hold
61,116
– – ﹤0.01% 2102
2021
Q2 		$1.67M Hold
61,116
– – ﹤0.01% 2043
2021
Q1 		$1.77M Buy
61,116
+40,000
+189% +$1.25M ﹤0.01% 2004
2020
Q4 		$594K Hold
21,116
– – ﹤0.01% 2069
2020
Q3 		$619K Buy
+21,116
New +$564K ﹤0.01% 2068

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Norges Bank's ARQT Position: Q2 2026 in Review

Norges Bank opened a new position in Arcutis Biotherapeutics (ARQT) in Q2 2026: 392,300 shares worth $10.3M. The stake represents ﹤0.01% of the portfolio and ranks #1285 among its holdings. This is a return to the name: Norges Bank previously reported a position in ARQT as recently as Q4 2025.

Norges Bank first reported a position in ARQT in Q3 2020 and has held it in 22 quarters since. The position peaked at $10.6M in Q1 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Norges Bank held 392,300 shares of Arcutis Biotherapeutics worth $10.3M as of Q2 2026.
  • Arcutis Biotherapeutics was a new Norges Bank position in Q2 2026.
  • Arcutis Biotherapeutics made up ﹤0.01% of Norges Bank's portfolio in Q2 2026, its #1285 holding.
  • Norges Bank first reported a position in Arcutis Biotherapeutics in Q3 2020 and has held it in 22 quarters since.
  • Norges Bank's Arcutis Biotherapeutics position peaked at $10.6M in Q1 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Norges Bank's 13F filing for Q2 2026, filed 12 Aug 2026.